Cargando…

Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

BACKGROUND: Mutations in the TERT promoter, ALK rearrangement, and the BRAF V600E mutation are associated with aggressive clinicopathologic features in thyroid cancers. However, little is known about the impact of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Ja Seong, Kim, Yourha, Jeon, Sora, Kim, Se Hee, Kim, Tae Jung, Lee, Sohee, Kim, Min-Hee, Lim, Dong Jun, Lee, Youn Soo, Jung, Chan Kwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746931/ https://www.ncbi.nlm.nih.gov/pubmed/26857243 http://dx.doi.org/10.1186/s13000-016-0458-6

Ejemplares similares

Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid
por: Bae, Ja-Seong, et al.
Publicado: (2014)

Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans
por: Kim, Sue Youn, et al.
Publicado: (2020)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

TERT Promoter and BRAF V600E Mutations in Papillary Thyroid Cancer: A Single-Institution Experience in Korea
por: Kim, Min Jhi, et al.
Publicado: (2022)

Erratum: Correction of Nomenclature of BRAF Mutation
por: Cho, Uiju, et al.
Publicado: (2014)

Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma
por: Kim, Yourha, et al.
Publicado: (2017)

Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors
por: Park, Charny, et al.
Publicado: (2015)

BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report
por: Sui, Aixia, et al.
Publicado: (2021)

Ultrasound and clinicopathological features of papillary thyroid carcinomas with BRAF and TERT promoter mutations
por: Hahn, Soo Yeon, et al.
Publicado: (2017)

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF(V600E)/TERT promoter double-mutated glioma
por: Gabler, Lisa, et al.
Publicado: (2019)

RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAF(V600E) Mutation-Negative Nodules?
por: Yoon, Jung Hyun, et al.
Publicado: (2015)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Clinicopathological Features of Rare BRAF Mutations in Korean Thyroid Cancer Patients
por: Cho, Uiju, et al.
Publicado: (2014)

Detection of Plasma BRAF(V600E) Mutation Is Associated with Lung Metastasis in Papillary Thyroid Carcinomas
por: Kim, Bo Hyun, et al.
Publicado: (2015)

CCND1 Splice Variant as A Novel Diagnostic and Predictive Biomarker for Thyroid Cancer
por: Jeon, Sora, et al.
Publicado: (2018)

BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases
por: Shin, Sang-Yong, et al.
Publicado: (2015)

False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
por: Paek, Se Hyun, et al.
Publicado: (2017)

Expression of NF2 Modulates the Progression of BRAF(V600E) Mutated Thyroid Cancer Cells
por: You, Mi-Hyeon, et al.
Publicado: (2019)

BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients
por: Sun, Jian, et al.
Publicado: (2016)

Proper Indication of BRAF(V600E) Mutation Testing in Fine-Needle Aspirates of Thyroid Nodules
por: Koh, Jieun, et al.
Publicado: (2013)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

Induction of the BRAF(V600E) Mutation in Thyroid Cells Leads to Frequent Hypermethylation
por: Yi, Jin Wook, et al.
Publicado: (2022)

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients
por: Ahn, Hyo Yeong, et al.
Publicado: (2023)

Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm
por: Oh, Hye-Seon, et al.
Publicado: (2018)

Is Follow-up BRAF(V600E) Mutation Analysis Helpful in the Differential Diagnosis of Thyroid Nodules with Negative Results on Initial Analysis?
por: Yoon, Jung Hyun, et al.
Publicado: (2013)

Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAF(V600E) mutations in papillary thyroid carcinoma
por: Yoon, Jung Hyun, et al.
Publicado: (2020)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area
por: Kim, Hyereen, et al.
Publicado: (2018)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement
por: Choi, Se Hoon, et al.
Publicado: (2017)

Discrepant Results for BRAF V600E Mutation Among Different Specimens in a Case of Hairy Cell Leukemia
por: Moon, Hee-Won, et al.
Publicado: (2013)

BRAF(V600E) and TERT promoter C228T mutations on ThyroSeq v3 analysis of delayed skin metastasis from papillary thyroid cancer: a case report and literature review
por: Choi, Jee-Hye, et al.
Publicado: (2023)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
por: Kim, Su-Jung, et al.
Publicado: (2019)

Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
por: Kang, So Young, et al.
Publicado: (2013)

The thyroid imaging reporting and data system on US, but not the BRAF(V600E) mutation in fine-needle aspirates, is associated with lateral lymph node metastasis in PTC
por: Park, Vivian Y., et al.
Publicado: (2016)

Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma
por: Lee, Seung Eun, et al.
Publicado: (2016)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7jge1ki3scfjhvf0roi7evdjfl